Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.72 |
| ▸ | LMNA | P02545 | 6/20 | 0.72 |
| ▸ | DRD2 | P14416 | 6/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.72 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.72 |
| ▸ | HTR2A | P28223 | 5/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.72 |
| ▸ | HRH1 | P35367 | 5/20 | 0.72 |
| ▸ | DRD3 | P35462 | 5/20 | 0.72 |
| ▸ | HTR2B | P41595 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.72 |
| ▸ | TP53 | P04637 | 5/20 | 0.72 |
| ▸ | HTR1A | P08908 | 5/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiopropazate SCHEMBL31153316 | 0.99 | MAPT (0.70) | MAPTLMNADRD2CYP2D6MAPK1 | |
| Thiopropazate SCHEMBL955966 | 0.99 | MAPT (0.70) | MAPTLMNADRD2CYP2D6MAPK1 | |
| Thiopropazate SCHEMBL955965 | 0.99 | MAPT (0.70) | MAPTLMNADRD2CYP2D6MAPK1 | |
| Thiopropazate SCHEMBL1651297 | 0.98 | MAPT (0.69) | MAPTLMNADRD2CYP2D6MAPK1 | |
| Thiopropazate SCHEMBL5972306 | 0.97 | DRD2 (0.77) | MAPTLMNADRD2CYP2D6MAPK1 | |
| SCHEMBL13464239 | 0.92 | CYP2D6 (0.73) | MAPTLMNADRD2CYP2D6MAPK1 | |
| SCHEMBL10084511 | 0.90 | DRD2 (0.69) | MAPTLMNADRD2CYP2D6MAPK1 | |
| Thiopropazate SCHEMBL13724873 | 0.90 | MAPT (0.71) | MAPTLMNADRD2CYP2D6MAPK1 | |
| SCHEMBL1041510 | 0.89 | DRD2 (0.68) | MAPTLMNADRD2CYP2D6MAPK1 | |
| SCHEMBL10084508 | 0.89 | DRD2 (0.67) | MAPTLMNADRD2CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| WO-2024107681-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| US-20240000810-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS | Orcosa Inc. (US) | 2024-01-04 | — | — | US | claimed |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | claimed |
| EP-4192579-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-06-14 | — | — | EP | claimed |
| WO-2022032077-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | REDUX THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| EP-3770159-A1 | BENZOQUINOLONE INHIBITOR OF VMAT2 | Auspex Pharmaceuticals, Inc. (US) | 2021-01-27 | — | — | EP | claimed |
| EP-3421469-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | Auspex Pharmaceuticals, Inc. (US) | 2019-01-02 | — | — | EP | claimed |
| EP-3351247-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | Auspex Pharmaceutical, Inc. (US) | 2018-07-25 | — | — | EP | claimed |
| US-5492907-A | ADMINISTERING AN ALPHA2-ADRENERGIC RECEPTOR ANTAGONIST AND A D2 DOPAMINE RECEPTOR ANTAGONIST; TREATS SCHIZOPHRENIA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1996-02-20 | — | — | US | claimed |
| US-5474783-A | In the form of sheet; used for applying to the dermis | NOVEN PHARMACEUTICALS, INC. (US) | 1995-12-12 | — | — | US | claimed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | claimed |
| EP-0591432-A4 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION. | NOVEN PHARMA (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0591432-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1994-04-13 | — | — | EP | claimed |
| WO-1993000058-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1993-01-07 | — | — | WO | claimed |
| EP-0180364-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOTHIAZINES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1990-03-07 | — | — | EP | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| EP-0174342-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES. | UNIV FLORIDA (US) | 1986-03-19 | — | — | EP | claimed |
| WO-1985003937-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1985-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | ACAT2, CPT1A, SLC18A2 | MAPT 1179/4885LMNA 1919/4885DRD2 2127/4885 |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | LIPC, CPT1A, CETP | MAPT 1631/4885LMNA 2305/4885DRD2 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.